United Kingdom Rheumatoid Arthritis Treatment Market By Treatment Type (Symptomatic Treatment, Intermediate Corticosteroid Therapies, Stem Cell Therapies, Drugs (Disease-modifying Anti-Rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDS), Corticosteroids, Uric Acid Drugs, Others), Others), By End User (Hospital & clinics, Ambulatory Care Centers, Other), By Region & Competition,
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited Kingdom Rheumatoid Arthritis Treatment Market By Treatment Type (Symptomatic Treatment, Intermediate Corticosteroid Therapies, Stem Cell Therapies, Drugs (Disease-modifying Anti-Rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDS), Corticosteroids, Uric Acid Drugs, Others), Others), By End User (Hospital & clinics, Ambulatory Care Centers, Other), By Region & Competition,
United Kingdom Rheumatoid Arthritis Market is expected to grow with an impressive rate during forecast period. Rheumatoid arthritis is a chronic autoimmune disorder where the body’s immune system attacks its own tissues particularly at lining of the joints. Based on the characterization by inflammation, pain, and swelling in affected joints, rheumatoid arthritis can be classified into Seropositive Rheumatoid Arthritis, Seronegative Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis (JRA), Felty's Syndrome, Still's Disease, Palindromic Rheumatism, and Rheumatoid Vasculitis. However, the most common type of rheumatoid arthritis which is prevalent among the population of United Kingdom is Seropositive rheumatoid arthritis. Some of the potential factors which can lead to the development of rheumatoid arthritis include abnormal immune response, fluctuations in hormonal levels, genetic factors, and others. Currently, in United Kingdom, there are around 400,000 people suffering from rheumatoid arthritis. Proper treatment of rheumatoid arthritis is necessary since it can increase the risk of developing osteoporosis, rheumatoid nodules, infections, carpal tunnel syndrome, heart problems, lung problems, and lymphoma. Certain medicines which are capable of decreasing the pain and inflammation caused after rheumatoid arthritis include non-steroidal anti-inflammatory drugs such as Ibuprofen, Naproxen, Aspirin, COX-2 inhibitors, Corticosteroids, and Disease-modifying antirheumatic drugs (DMARDs) such as Methotrexate, Sulfasalazine, Sulfasalazine, and others. Moreover, surgeries that can restore the function of severely damaged joints include knee replacement and hip replacement. United Kingdom Rheumatoid Arthritis Treatment Market is expected to be driven by several factors in the forecast period. Increase in prevalence of rheumatoid arthritis and complications related to it can contribute to increased mortality rates ,in some cases. This is expected to register an impressive growth to United Kingdom rheumatoid arthritis treatment market in upcoming years. Furthermore, development in the healthcare system of United Kingdom which is leading to improvement in treatment facilities for rheumatoid arthritis is also supporting the market growth. Growing ratio of geriatric population and emergence of osteoarthritis among them which is associated with wear and tear on the joints over time are also expected to propel the growth of United Kingdom Rheumatoid Arthritis Treatment Market in the forecast period.
Increasing Prevalence of Rheumatoid Arthritis
Moreover, as per the report published by UK Net, it has been concluded that around 387,000 adults have rheumatoid arthritis in United Kingdom which is the most common form of inflammatory arthritis. It affects around three times as many women as men. Approximately 200,000 people in UK are suffering from ankylosing spondylitis and around 177,000 are diagnosed with psoriatic arthritis. Furthermore, around 12,000 children under 16 years of age are affected with juvenile idiopathic arthritis (JIA).
Development in Healthcare Infrastructure
Growing development of United Kingdom’s healthcare system by establishment of well-equipped rheumatology clinics, imaging centers, infusion centers, and rehabilitation centers, are expected to propel the growth of United Kingdom rheumatoid arthritis treatment market in the forecast period. State-of -the- art facilities such as coil placement, sequences, Contrast-Enhanced MRI, and Bilateral Comparison which are helpful in accurate scanning of rheumatoid arthritis, are also contributing to the market growth. Moreover, availability of highly qualified healthcare professional in the region who are skilled in performing various laboratory tests such as Rheumatoid Factor (RF), Anti-Cyclic Citrullinated Peptide (anti-CCP) Antibodies, and Acute Phase Reactants for analysis of inflammation, synovitis, and tendon abnormalities is also promoting the treatment for rheumatoid arthritis in United Kingdom.
Growth in Geriatric Population
. Moreover, as per the analysis published by Statista in 2021, it has been concluded that around 12 % of total population in United Kingdom were aged between 50-49 years of age, followed by 14% of people aged between 50-59 years, 11 % of people aged between 60-69 years, 8% of people aged between 70-79 years of age, 5% people aged between 80-89 years of age, and so on.
Recent Developments
- In August 2019, AbbVie, a biopharmaceutical company, announced that it has received FDA approval for the RINVOQ (upadacitinib), an oral JAK Inhibitor for the treatment of moderate to severe rheumatoid arthritis.
- In July 2020, Mylan announced that the FDA had approved Hurio, a biosimilar to Humira. It is a TNF inhibitor used to treat patients with rheumatoid arthritis, juvenile degenerative arthritis, psoriatic arthritis, reactive arthritis spondylitis, adult Crohn's disease, gastrointestinal disorders, and psoriatic arthritis.
- Avsola, a biosimilar version of Remicade, a popular rheumatoid arthritis drug manufactured by Johnson & Johnson, received US Food and Drug Administration approval in December 2019.
Market Segmentation
United Kingdom Rheumatoid Arthritis Treatment Market is segmented based on Treatment Type, End User, Region, and Company. Based on treatment type, United Kingdom Rheumatoid Arthritis Treatment Market is divided into Symptomatic Treatment, Intermediate Corticosteroid Therapies, Stem Cell Therapies, Drugs (Disease-modifying Anti-Rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDS), Corticosteroids, Uric Acid Drugs, Others), and Others. On the basis of end user, United Kingdom Rheumatoid Arthritis Treatment market is fragmented into Hospital & clinics, Ambulatory Care Centers, and Others.
Market Players
Medtronic Ltd., 3m United Kingdom Public Limited, ConvaTec, Inc., Smith & Nephew plc., B. Braun Medical Ltd., Mölnlycke Health Care Limited, Novartis Pharmaceuticals UK Ltd., GlaxoSmithKline plc., AbbVie Ltd.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume in tons and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, Volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Treatment Type · End User |
| Regional scope | London, East Anglia, Southwest, Southeast, Scotland, East Midlands, Yorkshire & Humberside |
| Key companies profiled | Medtronic Ltd., 3m United Kingdom Public Limited, ConvaTec, Inc., Smith & Nephew plc., B. Braun Medical Ltd., Mölnlycke Health Care Limited, Novartis Pharmaceuticals UK Ltd., GlaxoSmithKline plc., AbbVie Ltd. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy